Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer EntitiesWolfgang P. Fendler, Rainer Hamacher, Lukas Kessler et al.|Clinical Cancer Research|2022Cited by 145
Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor EntitiesNader Hirmas, Wolfgang P. Fendler, Martin Glas et al.|Journal of Nuclear Medicine|2022Cited by 68
Superior Tumor Detection for<sup>68</sup>Ga-FAPI-46 Versus<sup>18</sup>F-FDG PET/CT and Conventional CT in Patients with CholangiocarcinomaKim M. Pabst, Wolfgang P. Fendler, Katja Steiger et al.|Journal of Nuclear Medicine|2023Cited by 63
<sup>68</sup>Ga-Labeled Fibroblast Activation Protein Inhibitor (<sup>68</sup>Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the<sup>68</sup>Ga-FAPI PET Observational TrialLukas Kessler, Jens T. Siveke, Ken Herrmann et al.|Journal of Nuclear Medicine|2023Cited by 34
Fibroblast Activation Protein α–Directed Imaging and Therapy of Solitary Fibrous TumorRainer Hamacher, Wolfgang P. Fendler, Daniel Hübschmann et al.|Journal of Nuclear Medicine|2024Cited by 26